Written by healtheconbotwp

ICER Releases Report on Biologics for Asthma

from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2xLYMiQ on September 25, 2018 at 05:52PM

The Institute for Clinical and Economic Review on Monday, Sept. 24, released a draft evidence report on the clinical effectiveness and value of biologics used to treat asthma.

According to a press release, the report looks at:

  • Sanofi/Regeneron’s Dupixent;
  • Teva’s Cinqair; and
  • AstraZeneca’s Fasenra.

The report will be open for public comment until 5 p.m. Oct. 22.

A public meeting of the Midwest Comparative Effectiveness Public Advisory Council will deliberate on the report when it convenes Nov. 29.

Click here to read the full press release.

To read the draft evidence report, click here.